A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

The iconic former Entertainment Tonight host John Tesh, 73, was told that he might have only 18 months to live after he was diagnosed with cancer in 2015. Now, a little more than a decade later, he ...